




Figure S1. CSDE1 isoforms in PMK and melanoma cells. (A) Depletion of CSDE1 in PMK (left) and in SK-Mel-147 (right) to confirm identity of bands. LRPPRC and tubulin are shown as loading controls. Asterisks denote non-specific bands. NI, not infected. NT, not transfected. **(B)** and **(C)** Snapshot of IGV tracks showing Nanopore read coverage for detected *csde1* transcripts. **(D)** Validation of exon 6 inclusion by semi-quantitative PCR.




Figure S2. CSDE1 transcript expression in squamous cell carcinoma (SCC). (A) Global CSDE1 mRNA levels in matched normal skin and cutaneous SCC patient samples. TPM, transcripts per million. Significance was assessed by t-test. (B) CSDE1 isoform expression in human (left) and mouse (right) samples. Preneoplastic papilloma is included in mice. Transcript identities are indicated on the right. Color code is as in Figures 1 and 2B. Significance was assessed with ANOVA (***) $P \leq 0.001$).




Figure S3. CSDE1 isoform replacement. **(A)** Intracellular localization of CSDE1-GFP isoforms assessed by wide-field fluorescent live imaging. Scale bar, 25 μ m. **(B)** CSDE1 isoform expression in UACC-62 cells. Representative Western blot showing both endogenous and exogenous CSDE1 upon depletion (shCSDE1) or not (shCtrl) of the endogenous protein. Vinculin is used as loading control. **(C)** Effect of individual CSDE1 isoforms on UACC-62 anoikis resistance. Box plots represent two biological replicates with five technical replicates. Values were normalized to the average of shCTRL-GFP samples. Significance was assessed by Student's t-test (* $P \leq 0.05$, ** $P \leq 0.01$).




Figure S4. CSDE1 intracellular localization in cells of melanocytic origin. CSDE1 Western blots shown in Fig 7A with the corresponding fractionation controls. Markers for nuclei (EZH2), cytosol (Tubulin) and membrane fractions (HSP47, VDAC) were used. TL, total lysate; N, nucleus; C, cytosol; M, membranes.